Skip to main content

Table 4 Exploratory analyses of total symptom scores, ANCOVA-adjusted means

From: Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial

    I-C vs. placebo
  N Adjusteda mean (SE) Adjusteda mean (SE) differenceb 95 % CI p-value*
TSS2–4, ex 1 pt      
 I-C 97 5.67 (0.24) −0.72 (0.34) (−1.40, −0.05) 0.0364
 Placebo 97 6.39 (0.24)    
TSS1-4      
 I-C 98 6.02 (0.21) −0.60 (0.30) (−1.19, −0.00) 0.0495
 Placebo 97 6.62 (0.21)    
TSS1–4, rel      
 I-C 98 −0.08 (0.05) −0.13 (0.06) (−0.25, −0.01) 0.0421
 Placebo 97 0.05 (0.05)    
Subset analyses      
TSS2–4, virus positive patients      
 I-C 53 5.87 (0.34) −0.80 (0.48) (−1.75, 0.15) 0.0986
 Placebo 54 6.67 (0.34)    
TSS2–4, HRV/HEV positive patients      
 I-C 27 6.08 (0.46) −0.36 (0.65) (−1.66, 0.94) 0.5820
 Placebo 28 6.44 (0.46)    
  1. CI confidence interval
  2. *For ANCOVA-adjusted comparison of placebo with I-C
  3. aThe means were adjusted for baseline TSS
  4. bA negative treatment difference favours I-C